Detailed Information on Publication Record
2009
Monitoring of immunosuppressive cytokines in glioblastoma
VAŇHARA, Petr, Sabina ŠEVČÍKOVÁ, Jiří ŠMEJKAL, Marek SOVA, Martin SMRČKA et. al.Basic information
Original name
Monitoring of immunosuppressive cytokines in glioblastoma
Name in Czech
Monitorování imunosupresivních cytokinů u glioblastomu
Authors
VAŇHARA, Petr (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic), Jiří ŠMEJKAL (203 Czech Republic), Marek SOVA (203 Czech Republic), Martin SMRČKA (203 Czech Republic), Leoš KŘEN (203 Czech Republic), Jan ŠMARDA (203 Czech Republic, guarantor) and Jaroslav MICHÁLEK (203 Czech Republic)
Edition
qPCR Congress 2009, London, 2009
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14310/09:00037268
Organization unit
Faculty of Science
Keywords (in Czech)
glioblastom; imunosuprese; TGFbeta; qRT-PCR
Keywords in English
glioblastoma; immunosuppresion; TGFbeta; qRT-PCR
Tags
International impact
Změněno: 1/4/2010 15:33, prof. RNDr. Jan Šmarda, CSc.
V originále
Multiform glioblastoma (GBM) is by far the most malignant form of primary brain tumors with limited therapeutic options. Median survival is estimated approximately to 12 months with less than 25% of patients surviving up to 2 years after diagnosis and less than 10% surviving up to 5 years. Despite great efforts, standard therapy based on neurosurgery, chemo- and radiotherapy fails. GBM tumors often avoid immune surveillance by inhibition of infiltrating immune cells by paracrine signaling. Among these factors, proteins of TGFb family are highly involved. In this study, we focused on expression of TGFbeta1-3, BMP-7, BMP-9, GDF-15 and other growth factors, immunomodulators or tumor-associated genes in samples of patients newly diagnosed for GBM. These samples were analyzed by quantitative PCR and normalized either to control, healthy brain tissue, or non-malignant disease. We found significant change of expression several genes of TGFbeta family that correlates with development of malignant disease. This study can contribute to better understanding of the strong immune suppressive phenomenon in GBM patients. This study is supported by IGA9875-4 of Ministry of Health of the Czech Republic.
In Czech
Glioblastoma multiforme patří mezi maligní nádory mozku s velmi špatnou prognózou. Charakteristickým rysem tohoto onemocnění je silná imunosuprese vyvolaná maligním procesem. Tato práce se soustřeďuje na popis exprese vybraných imunosupresivních cytokinů (zejména TGFbeta) a genů potenciálně asociovaných s nádorovým onemocněním.
Links
| MSM0021622415, plan (intention) |
|